Century Therapeutics (IPSC) Interest Expenses (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Interest Expenses of $69.2 million for Q1 2026, up 17342.57% year-over-year from N/an in Q1 2025, and up 1154016.67% quarter-over-quarter from $6000.0 in Q4 2025.
Century Therapeutics (IPSC) Interest Expenses (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Interest Expenses for 7 consecutive years, with $69.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 17342.57% year-over-year to $69.2 million; the TTM figure through Mar 2026 stood at $69.2 million (up 5356.82% YoY), while the FY2025 annual figure was $1.0 million, down 99.48% from the prior year.
- Interest Expenses climbed to $69.2 million in Q1 2026 per IPSC's latest filing, from $6000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $192.2 million in Q4 2024 and bottomed at -$46000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $34.2 million across 5 years, with a median of $514000.0 in 2023.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 114.84% — and 2024, when it soared 417989.13%.
- Century Therapeutics' Interest Expenses stood at $310000.0 in 2022, then slumped by 114.84% to -$46000.0 in 2023, then jumped by 417989.13% to $192.2 million in 2024, then tumbled by 100.0% to $6000.0 in 2025, then jumped by 1154016.67% to $69.2 million in 2026.
- Business Quant data shows IPSC's Interest Expenses at $69.2 million in Q1 2026, $6000.0 in Q4 2025, and $21.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 55.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.81 Mn |
| Jun 30, 2026 | 55.81 Mn |
| Mar 31, 2026 | 69.25 Mn |
| Mar 31, 2026 | 69.25 Mn |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 21.44 Mn |
| Sep 30, 2025 | 21.44 Mn |
| Jun 30, 2025 | 24.12 Mn |
| Jun 30, 2025 | 24.12 Mn |
| Mar 31, 2025 | 397,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Dec 31, 2024 | 192.23 Mn |
| Dec 31, 2024 | 192.23 Mn |
| Sep 30, 2024 | 87.00 Mn |
| Sep 30, 2024 | 87.00 Mn |
| Jun 30, 2024 | 94.51 Mn |
| Jun 30, 2024 | 94.51 Mn |
| Mar 31, 2024 | 81.87 Mn |
| Mar 31, 2024 | 81.87 Mn |